Stent thrombosis (ST) is an uncommon but highly morbid complication of percutaneous coronary intervention (PCI), with 10% to 20% mortality at 1 year (1) (2) (3) (4) . Causes of ST can be grouped according to factors related to the stent, the procedure, and the patient (5) . Early ST (occurring within 1 month of stent implantation) is more commonly due to procedure-related complications (6) . In contrast, late ST (occurring 1 to 12 months after stent implantation) and very late See page 141
ST (occurring Ն12 months after stent implantation) may be caused by impaired re-endothelialization, stent malapposition or fracture, a hypersensitivity reaction to the polymer used in drug-eluting stents (DES), or de novo plaque rupture (7) (8) (9) (10) . Inadequate antiplatelet therapy and/or resistance to antiplatelet agents are also associated with an increased risk for ST (11, 12) . DES have a similar rate of early and late ST relative to bare-metal stents (BMS), but DES may be associated with increased rates of very late ST (13) . These heterogeneous causes of ST may result in different presentations and outcomes for early, late, and very late ST. Prior studies have identified clinical predictors of ST after stent implantation (2, 14, 15) , but most of these studies have limited power to detect differences in rates of major adverse cardiovascular events with treatment for early, late, or very late ST. To address this gap in knowledge, we identified definite, angiographically documented, ST in the CathPCI registry and analyzed differences in the presentation, treatment, and in-hospital mortality of ST as a function of time since original stent implantation.
Methods
Study population. The CathPCI registry (version 4.3) is an initiative of the American College of Cardiology Foundation and the Society for Cardiovascular Angiography and Interventions. The registry receives data from over 1,000 participating hospitals across the United States, and its database includes demographic factors, procedural details, and in-hospital outcomes of patients undergoing coronary angiography and PCI. The CathPCI registry is composed of standard data collection forms with explicit data definitions, uniform data entry and transmission requirements, and data quality checks (16) . The NCDR (National Cardiovascular Data Registry) has a data quality program in place to ensure consistent and reliable data. The institutional review board of each hospital approved participation in the CathPCI registry. Participating sites collected data in an anonymous fashion for consecutive patients who met the inclusion criteria during the initial hospitalization. Built-in data quality checks include exclusion of outliers, edit checks at time of entry, consistency checks, quarterly reports, and random site audits by trained abstractors. In addition, participating facilities are afforded a wide variety of training options. Details on the data collection process have previously been published, and the data definitions can be found at NCDR's Website (17) . All data elements were proposed by the CathPCI Version 4 Dataset Workgroup, reviewed by the CathPCI Steering Committee, and approved by the NCDR Science Quality and Oversight Committee. Data elements are recorded at the time of cardiac catheterization and then forwarded electronically to a secure data server stored at the ACC Heart House in Washington, DC.
For this study, we examined registry patients undergoing PCI procedures from February 3, 2009, through June 29, 2010 . ST was identified using a pre-defined data element for ST by the participating centers at the time of PCI according to Figure 1 . To ensure quality of data recording and to model closely the Academic Research Consortium definition of definite ST (18), we also required the angiographer to indicate that the patient presented with an acute coronary syndrome; that a prior PCI had occurred; and that ST was present. To refine the cohort, we excluded any subject in which the lesion was encoded as a chronic total occlusion or if the date of implantation of the thrombosed stent was missing or unknown. Furthermore, in cases where initial flow was categorized as Thrombolysis In Myocardial Infarction (TIMI) flow grade 3, the case was excluded if the operator failed to indicate the presence of visible thrombus at the time of intervention. Early ST was defined as occurring within 1 month of prior stent implantation, late as 1 to 12 months, and very late as Ͼ1 year.
Baseline demographics and procedural details were reported by participating centers. Race/ethnicity was based on patient or family self-report, with options consisting of white, black, Hispanic, Asian, Native American, or other. Because the CathPCI registry only contains data related to a given PCI procedure (i.e., there is no ability to link patients across different interventions), procedural details of the initial stent implantation could not be ascertained other than the initial stent type (BMS vs. DES). This study was approved by the Duke University Medical Center and was determined to meet criteria for research not requiring informed consent. Clinical endpoints. The primary endpoint was in-hospital mortality. Secondary endpoints during the hospital admission included occurrence of a cerebrovascular event (defined as a focal neurologic deficit lasting Ͼ24 h due to an ischemic or hemorrhagic cause), a bleeding event within 72 h (defined as Ն3 g/dl drop in hemoglobin, transfusion of whole blood or packed red blood cells, or an intervention or surgical procedure to correct bleeding related to the PCI), and lesion treatment success (defined as TIMI flow grade 3 in the culprit vessel at the conclusion of the procedure). Statistical analysis. Baseline patient subgroups are presented as counts with percentages for categorical variables and median with interquartile range for continuous variables. Statistical comparison of between-group differences was performed using chi-square test for categorical variables and analysis of variance or the Kruskal-Wallis test for continuous variables. Statistical significance was defined as p Ͻ 0.05 for all comparisons. All statistical analyses were performed by the Duke Clinical Research Institute using SAS (version 9.3, SAS Institute, Cary, North Carolina).
Multivariable logistic regression modeling with generalized estimating equations was performed to evaluate if the timing of ST was an independent predictor of in-hospital mortality while adjusting for within hospital correlation using a previously validated model for mortality after PCI (19) . Early ST was used as the reference group. Variables in the mortality model included: age, sex, race, presentation with ST-segment elevation myocardial infarction (STEMI), cardiogenic shock, previous heart failure, cerebrovascular disease, peripheral vascular disease, chronic lung disease, glomerular filtration rate, dialysis, New York Heart Association functional class heart failure, highest risk segment category, PCI status, diabetes, and lesion bifurcation.
Results
A total of 7,315 ST cases with known timing occurred in 7,079 patients at 977 hospitals during the study period ( Fig. 1 ). Stent thromboses represented 1.8% of all PCI for acute coronary syndromes during the study period. A total of 1,391 early, 1,370 late, and 4,318 very late ST were identified, representing 19.6%, 19.4%, and 60% of the study population, respectively. Among subjects with very late ST, 925 (21.4%) occurred 1 to 2 years after an index PCI, and 3,393 (78.6%) occurred Ն2 years after index PCI.
Patient characteristics differed based on the timing of ST ( Table 1 ). The prevalence of black race, diabetes, and prior heart failure was highest among subjects with early ST, and these subjects were more likely to present with cardiogenic shock than the other ST groups were. Patients with late ST were more likely to have previous coronary artery bypass graft and renal failure and to present with unstable angina rather than acute myocardial infarction. The group presenting with very late ST had the highest prevalence of white race and a lower prevalence of prior myocardial infarction, renal failure, or diabetes.
Most patients had TIMI flow grade 0 (complete thrombotic occlusion) on initial coronary angiography (Table 2) ; TIMI flow grade 0 was more common in early ST (82%) than in late (61.9%) or very late ST (68.3%). The culprit lesion was more commonly located in the left anterior descending coronary artery (48%) in patients with early and late ST, whereas ST of the right coronary artery was more common (38%) among subjects with very late ST. Aspiration thrombectomy was performed in 29% to 34% of patients. More than one-half of patients had a new stent placed during treatment for ST. The rate of new stent placement was lowest in early ST (51.2%) and highest in very late ST (69.9%). A new DES was placed in 47% of patients with very late ST, and 23% of patients had a BMS placed (Fig. 2) . Subjects with ST of a previously implanted DES were more likely to have a new DES placed as treatment for the ST event. Subjects with ST of a previously implanted BMS were more likely to have a BMS placed as treatment for the ST event if the event was early or Patients with early ST had a greater likelihood of stroke (1%) and major bleeding events (5.4%) than patients with late or very late ST did (p Ͻ 0.001 for stroke; p ϭ 0.003 for bleeding) (Table 3) . Unadjusted in-hospital mortality was higher for early ST (7.9%) than for late (3.8%) or very late ST (3.6%, p Ͻ 0.001). Mortality was higher for early ST across the spectrum of acute coronary syndromes, with the highest mortality in patients with STEMI due to early ST (Fig. 3) . These mortality trends were similar for patients with ST from a DES or BMS (Fig. 4) . The lower mortality for late and very late ST persisted after multivariable adjustment, compared Values are n (%).
LAD ϭ left anterior descending artery; LMWH ϭ low molecular-weight heparin; RCA ϭ right coronary artery; TIMI ϭ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1 .
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Outcomes After ST (Table 4 ). These trends were unchanged and remained statistically significant if the analysis was limited only to patients presenting with STEMI or non-STEMI.
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Discussion
This analysis represents the largest reported series on the presentation and outcomes of ST in a contemporary PCI setting. Because of the likelihood of disparate underlying etiologies of early, late, and very late ST, we hypothesized that significant differences would exist among these important clinical subgroups. The large sample size of the Cath-PCI registry enabled us to make comparisons among groups that have not been possible with smaller reported case series. Three major findings emerged from this study. First, there were significant differences in the baseline characteristics and presentation of patients undergoing PCI for treatment of early, late, and very late ST, supporting the notion of differing etiologies. Second, most ST cases presented more than 1 year after stent implantation. Third, ST presenting within 1 month of stent implantation was associated with a significantly higher risk of in-hospital mortality than ST occurring more than 1 month after initial treatment. Presentation of early, late, and very late ST. We observed significant baseline differences among patients with ST, depending on the time since stent implantation. These differences in baseline clinical characteristics, as a function of ST timing, lend support to the hypotheses that differing underlying mechanisms cause early, late, and very late ST.
In the recent RESTART (Registry of Stent Thrombosis of Sirolimus-Eluting Stents), late ST, compared with very late ST, was associated with presence of heart failure, hemodialysis, diabetes, and low body mass index (2). Our confirmation of a higher prevalence of renal failure among subjects undergoing PCI for late ST suggests that renal dysfunction may mediate late ST, possibly due to increased restenosis with superimposed thrombosis (20, 21) . Other studies have also found a lower prevalence of diabetes among patients with very late ST compared with early ST, supporting the hypothesis that patients with diabetes may have an altered acute inflammatory response to stent placement (2, 22) . A recent study also found an association between black race and development of ST irrespective of medication compliance or socioeconomic status (23).
Because we had access only to in-hospital data at the time of ST, we were unable to investigate further any possible association between race and development of ST.
The overall rate of presentation with STEMI in our cohort was similar to previous reports, in which STEMI has represented 70% to 80% of cases of ST. The higher Values are n (%).
ST ϭ stent thrombosis. Figure 3 . In-Hospital Mortality Based on Presentation With Unstable Angina, Non-STEMI, or STEMI
The p values are: 0.06 for unstable angina; 0.038 for non-STEMI; and Ͻ0.001 for STEMI. STEMI ϭ ST-segment elevation myocardial infarction.
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Outcomes After ST prevalence of complete thrombotic occlusion in the culprit vessel among patients with early ST may reflect increased predisposition to thrombosis or increased prevalence of mechanical complications related to stent implantation. Our finding that subjects with very late ST were more likely to have TIMI flow grade 2 or 3 at the time of angiography is consistent with recent reports (2) . Somewhat surprisingly, we found that only one-half of patients were treated with aspiration thrombectomy at the time of ST, and that almost one-half of patients had a new stent implanted at the time of ST. Although data on outcomes after ST are limited, the high thrombus burden of patients with ST would suggest that aspiration thrombectomy might improve short-and possibly long-term outcomes. Additionally, implantation of a new stent at the time of ST has been associated with adverse long-term outcomes. The recent large registry of Japanese patients with ST of sirolimus-eluting stents had slightly higher rates of aspiration thrombectomy, but patients in that registry were also treated with new stent implantation 36% of the time. Further studies of ST with long-term follow-up are needed to identify management strategies at the time of ST that improve long-term outcomes. High prevalence of very late ST. In this study, we found that very late ST had a higher prevalence than early or late ST among subjects undergoing PCI, with most events occurring more than 2 years after initial stent implantation. Our findings do not suggest that very late ST has a higher incidence than early or late ST does. The CathPCI registry is a cross-sectional design, such that the denominator of patients at risk of ST is uncertain. Previous studies, including a Dutch registry of BMS and DES and a Japanese registry limited to sirolimus-eluting DES, were prospective studies that were able to identify the incidence of ST among a stable population with a defined length of follow-up. Consistent with this design, those studies suggested that very late ST represents only 13% to 30% of all cases of ST (2, 14) . In comparison, this study identified all-comers with CHF ϭ congestive heart failure; CI ϭ confidence interval; CVD ϭ cardiovascular disease; NYHA ϭ New York Heart Association; OR ϭ odds ratio;
PCI ϭ percutaneous coronary intervention; PVD ϭ peripheral vascular disease; other abbreviations as in Table 1 .
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ST, including those with DES or BMS. These differences in methodology may account for the high prevalence of very late ST: early and late ST by definition consist of limited time frames, whereas very late ST comprises the continued exposure to a stent from 1 year to many years after initial implantation. In the CathPCI registry, therefore, the total number of patient-years with exposure to risk of very late ST is greater than the patient-year exposure to early or late ST, so it is not unexpected that very late events would predominate with this study design. Our findings of a high population prevalence of very late ST are also similar to that of a recent multicenter observational study of angiographically confirmed ST (24) . Nonetheless, our results emphasize the high population prevalence and public health importance of preventing very late ST. Recent studies have suggested that very late ST occurs with a constant incidence of 0.5% per year for BMS and up to 1.9% per year for DES (22, 25) . Our findings also raise concerns that very late ST remains a continued risk years after PCI; that a significant number of ST occur Ͼ2 years after stent implantation; and that further studies are warranted to address the utility of continuing antiplatelet therapy beyond 1 year (26) . High mortality of early ST. The in-hospital mortality risk associated with early ST is high and significantly greater than for patients with late or very late ST. The observed 9.15% in-hospital mortality from STEMI from early ST is dramatically higher than the reported 5.5% mortality from the overall population of contemporaneous patients in the NCDR registry presenting with STEMI (27) . This finding is consistent with previous studies, suggesting that STEMI from ST is associated with higher mortality than STEMI from a de novo lesion (3). This increased mortality may reflect a pre-disposition to thrombosis, higher thrombus burden, or complications of the initial PCI (28) . Notably, early ST but not late or very late ST is associated with high on-treatment platelet reactivity, suggesting that patients with early ST may have a pre-disposition to thrombosis and subsequent adverse outcomes (29, 30) . The increased use of mechanical support, glycoprotein IIb/IIIa inhibitors, and prasugrel among patients with early ST suggest that moreintensive therapies were administered to this critically ill subgroup. Despite this, the increased risk of mortality in the early ST subgroup remained after multivariable adjustment for baseline factors using a previously validated model for mortality after myocardial infarction. Given the lack of therapies specific to ST, and the high risk of mortality, stroke, and bleeding that are associated with it, this study underscores the importance of continued efforts to identify modifiable predictors of this dreaded complication. Study limitations. The results of this study should be interpreted in the context of several potential limitations. First, because the CathPCI registry does not link patients across cases, we could not ascertain the details of the initial PCI associated with the initial stent implantation, such as stent length, the number of stents implanted, vessel sizes, complications of the initial procedure, or use of intravascular ultrasound. However, these procedural risk factors for ST have been well described in previous studies (2, 4) . Second, the data collected in the CathPCI registry does not include compliance to medications. Therefore, we cannot ascertain the prevalence of medication noncompliance or timing of antiplatelet discontinuation before ST. Whereas antiplatelet medication adherence is an important risk factor for ST, the emphasis of our study was on management and outcomes of ST, rather than on predictors of developing ST. Third, the identification of ST was based on operator identification and report without an angiographic core laboratory. Overor underreporting of ST may have occurred; however, we did employ multiple strategies to ensure that the cases had a clinical presentation consistent with ST. Fourth, this study was only able to identify cases of ST for which patients underwent PCI and, therefore, does not include patients with probable or possible ST as defined by the Academic Research Consortium criteria, or ST patients managed without PCI. This limitation, along with a "survivor bias" (e.g., ST resulting in pre-hospital death was not captured) may have resulted in underestimation of the true prevalence of ST in the entire population of stented patients. Alternatively, there could be a selection bias due to different proportions of out-of-hospital deaths related to the timing of ST. Finally, the outcomes of this study are limited to in-hospital events. As with other observational studies, the association of early ST with increased mortality does not necessarily confer causality.
Conclusions
Early, late, and very late ST have significant differences in presentation that may reflect different underlying causes of ST as a function of timing after the initial stent implantation. Most patients with early ST were treated with balloon angioplasty, whereas patients with very late ST were more frequently treated with DES. Early ST, compared with late or very late ST, is associated with higher in-hospital mortality after multivariable adjustment for baseline clinical characteristics.
